FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010231427> ?p ?o ?g. }

• W2010231427 endingPage "277" @default.
• W2010231427 startingPage "266" @default.
• W2010231427 abstract "Ceftolozane/tazobactam is under clinical development for treatment of complicated intra-abdominal infections (IAI), complicated urinary tract infections (UTI) and ventilator-associated pneumonia. We evaluated the in vitro activity of ceftolozane/tazobactam and comparator agents tested against Gram-negative aerobic bacteria causing IAI and healthcare-associated UTI (HCA-UTI). The organisms were consecutively collected from January to December 2012 from 59 medical centers located in the United States (USA) and 15 European countries by the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS). The collection included 809 organisms from IAI and 2474 organisms from HCA-UTI, and susceptibility testing was performed by reference broth microdilution methods as described by the Clinical and Laboratory Standards Institute (CLSI) M07-A9 document. Overall, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa were the most frequently isolated pathogens from both infection types. Ceftolozane/tazobactam was very active against E. coli (MIC50/90, 0.25/0.5 mg/L; 98.5–99.9% inhibited at an MIC of ≤8 mg/L) and retained activity against many of the multidrug-resistant (MDR; MIC50/90, 0.5/2–>32 mg/L) and ESBL-phenotype strains (MIC50/90, 0.5/2–32 mg/L). Ceftolozane/tazobactam was active against most K. pneumoniae strains (MIC50/90, 0.25/16 mg/L, 88.9–89.6% inhibited at an MIC of ≤8 mg/L), but some ESBL-phenotype (MIC50/90, 4–8/>32 mg/L) and MDR (MIC50/90, 16/>32 mg/L) isolates exhibited elevated MIC values. Ceftolozane/tazobactam was the most active agent tested against P. aeruginosa (MIC50/90, 0.5/4 mg/L; 93.4–95.7% inhibited at ≤8 mg/L) and retained potency against many MDR (MIC50/90, 2–4/>32 mg/L), ceftazidime-nonsusceptible (MIC50/90, 2–4/>32 mg/L) and meropenem-nonsusceptible (MIC50/90, 2/>32 mg/L) strains. Ceftolozane/tazobactam was also active against Klebsiella oxytoca (MIC50/90, ≤0.12–0.25/0.5–1 mg/L), Enterobacter spp. (MIC50/90, 0.25–0.5/4–8 mg/L), Citrobacter spp. (MIC50/90, 0.25/2–32 mg/L), Proteus mirabilis (MIC50/90, 0.5/0.5 mg/L), indole-positive Proteae (MIC50/90, 0.25/0.5–1 mg/L), and Serratia spp. (MIC50/90, 0.5/1–2 mg/L). In summary, ceftolozane/tazobactam demonstrated potent in vitro activity when tested against contemporary aerobic Gram-negative pathogens causing IAI and HCA-UTI in USA and European medical centers." @default.
• W2010231427 created "2016-06-24" @default.
• W2010231427 creator A5006715126 @default.
• W2010231427 creator A5008542312 @default.
• W2010231427 creator A5026620873 @default.
• W2010231427 creator A5037843249 @default.
• W2010231427 date "2014-09-01" @default.
• W2010231427 modified "2023-10-16" @default.
• W2010231427 title "Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)" @default.
• W2010231427 cites W1552481588 @default.
• W2010231427 cites W1971489011 @default.
• W2010231427 cites W1999704213 @default.
• W2010231427 cites W2048871400 @default.
• W2010231427 cites W2058450864 @default.
• W2010231427 cites W2078250306 @default.
• W2010231427 cites W2096724428 @default.
• W2010231427 cites W2120054881 @default.
• W2010231427 cites W2127827046 @default.
• W2010231427 cites W2138299373 @default.
• W2010231427 cites W2142343447 @default.
• W2010231427 cites W2146291304 @default.
• W2010231427 cites W2149186506 @default.
• W2010231427 cites W2152301214 @default.
• W2010231427 cites W2162282209 @default.
• W2010231427 doi "https://doi.org/10.1016/j.jinf.2014.04.004" @default.
• W2010231427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24780763" @default.
• W2010231427 hasPublicationYear "2014" @default.
• W2010231427 type Work @default.
• W2010231427 sameAs 2010231427 @default.
• W2010231427 citedByCount "70" @default.
• W2010231427 countsByYear W20102314272014 @default.
• W2010231427 countsByYear W20102314272015 @default.
• W2010231427 countsByYear W20102314272016 @default.
• W2010231427 countsByYear W20102314272017 @default.
• W2010231427 countsByYear W20102314272018 @default.
• W2010231427 countsByYear W20102314272019 @default.
• W2010231427 countsByYear W20102314272020 @default.
• W2010231427 countsByYear W20102314272021 @default.
• W2010231427 countsByYear W20102314272022 @default.
• W2010231427 countsByYear W20102314272023 @default.
• W2010231427 crossrefType "journal-article" @default.
• W2010231427 hasAuthorship W2010231427A5006715126 @default.
• W2010231427 hasAuthorship W2010231427A5008542312 @default.
• W2010231427 hasAuthorship W2010231427A5026620873 @default.
• W2010231427 hasAuthorship W2010231427A5037843249 @default.
• W2010231427 hasConcept C104317684 @default.
• W2010231427 hasConcept C126322002 @default.
• W2010231427 hasConcept C176947019 @default.
• W2010231427 hasConcept C2777058267 @default.
• W2010231427 hasConcept C2777637488 @default.
• W2010231427 hasConcept C2778266534 @default.
• W2010231427 hasConcept C2779631663 @default.
• W2010231427 hasConcept C2780950330 @default.
• W2010231427 hasConcept C501593827 @default.
• W2010231427 hasConcept C523546767 @default.
• W2010231427 hasConcept C54355233 @default.
• W2010231427 hasConcept C547475151 @default.
• W2010231427 hasConcept C55493867 @default.
• W2010231427 hasConcept C71924100 @default.
• W2010231427 hasConcept C77411442 @default.
• W2010231427 hasConcept C86803240 @default.
• W2010231427 hasConcept C89423630 @default.
• W2010231427 hasConcept C94665300 @default.
• W2010231427 hasConceptScore W2010231427C104317684 @default.
• W2010231427 hasConceptScore W2010231427C126322002 @default.
• W2010231427 hasConceptScore W2010231427C176947019 @default.
• W2010231427 hasConceptScore W2010231427C2777058267 @default.
• W2010231427 hasConceptScore W2010231427C2777637488 @default.
• W2010231427 hasConceptScore W2010231427C2778266534 @default.
• W2010231427 hasConceptScore W2010231427C2779631663 @default.
• W2010231427 hasConceptScore W2010231427C2780950330 @default.
• W2010231427 hasConceptScore W2010231427C501593827 @default.
• W2010231427 hasConceptScore W2010231427C523546767 @default.
• W2010231427 hasConceptScore W2010231427C54355233 @default.
• W2010231427 hasConceptScore W2010231427C547475151 @default.
• W2010231427 hasConceptScore W2010231427C55493867 @default.
• W2010231427 hasConceptScore W2010231427C71924100 @default.
• W2010231427 hasConceptScore W2010231427C77411442 @default.
• W2010231427 hasConceptScore W2010231427C86803240 @default.
• W2010231427 hasConceptScore W2010231427C89423630 @default.
• W2010231427 hasConceptScore W2010231427C94665300 @default.
• W2010231427 hasIssue "3" @default.
• W2010231427 hasLocation W20102314271 @default.
• W2010231427 hasLocation W20102314272 @default.
• W2010231427 hasOpenAccess W2010231427 @default.
• W2010231427 hasPrimaryLocation W20102314271 @default.
• W2010231427 hasRelatedWork W2146919056 @default.
• W2010231427 hasRelatedWork W2761021459 @default.
• W2010231427 hasRelatedWork W2903615114 @default.
• W2010231427 hasRelatedWork W3005536015 @default.
• W2010231427 hasRelatedWork W3094496711 @default.
• W2010231427 hasRelatedWork W3097647920 @default.
• W2010231427 hasRelatedWork W3132092684 @default.
• W2010231427 hasRelatedWork W4200194760 @default.
• W2010231427 hasRelatedWork W4220747811 @default.
• W2010231427 hasRelatedWork W4320305485 @default.
• W2010231427 hasVolume "69" @default.
• W2010231427 isParatext "false" @default.

• next